Experimental Alzheimer's drug could slow cognitive decline in patients, early results suggest
CNN
Eli Lilly and Company's experimental intravenous drug donanemab could slow the cognitive decline of patients with Alzheimer's disease, according to early clinical trial results, published in The New England Journal of Medicine on Saturday.
The study included 257 patients with early symptomatic Alzheimer's disease; 131 received donanemab, while 126 received a placebo. The researchers found donanemab slowed the decline of cognition and daily function in Alzheimer's patients by 32% after 76 weeks, compared to those who received a placebo. Taken over 18 months, that 32% slowing of decline could be noticeably impactful for Alzheimer's patients, noted Maria Carrillo, chief science officer at the Alzheimer's Association, who was not involved in the study.President Joe Biden is expected to announce an executive order as early as Tuesday that would effectively shut down the US-Mexico border to asylum-seekers crossing illegally when a daily threshold of crossings is exceeded – a sweeping and controversial proposal that is likely to receive fierce pushback from progressives and immigration advocates.
In the days and weeks leading up Hunter Biden’s trial on felony gun charges, President Joe Biden made little attempt to distance himself from his son. Instead, Hunter Biden was seen at the White House and in Delaware at his father’s side amid what the president’s allies acknowledge is a difficult moment for both men.